Axcella Announces Upcoming Investor Conference Presentation

Rhea-AI Summary

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The presentation, focusing on their approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions, will be available via a live audio webcast at 7:00 a.m. ET. A replay will be accessible for 90 days. Axcella's pipeline includes candidates aimed at reducing the risk of overt hepatic encephalopathy recurrence and treating non-alcoholic steatohepatitis.

H.C. Wainwright 23rd Annual Global Investment Conference presentation and webcast to be available on September 13

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference.

A live audio webcast of this discussion will be available on the “Investors & News” section of the company’s website, www.axcellahealth.com, at 7:00 a.m. ET on September 13, 2021. A replay will also be available on Axcella’s website for 90 days following the presentation.

Internet Posting of Information

Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors & News” section. Accordingly, investors should monitor this portion of the company’s website, in addition to its press releases, SEC filings and public conference calls and webcasts.

About Axcella

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence and the treatment of non-alcoholic steatohepatitis (NASH). For more information, please visit www.axcellahealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005500/en/

Company Contact

Jason Fredette

jfredette@axcellahealth.com

857.320.2236

Source: Axcella

FAQ

What is Axcella's presentation at the H.C. Wainwright Conference about?

Axcella will discuss their treatment approaches for complex diseases using endogenous metabolic modulator compositions.

When is Axcella's presentation scheduled at the conference?

The presentation is scheduled for September 13, 2021, at 7:00 a.m. ET.

Where can I watch Axcella's presentation?

The live audio webcast will be available on Axcella's website in the 'Investors & News' section.

How long will the replay of Axcella's presentation be available?

The replay will be available for 90 days following the presentation.

What are Axcella's main product candidates?

Axcella's pipeline includes candidates for reducing the risk of overt hepatic encephalopathy recurrence and treating non-alcoholic steatohepatitis.

What is the significance of Axcella's EMM compositions?

Axcella's EMM compositions are engineered to simultaneously impact multiple biological pathways for better health outcomes.